SCHEMBL4673102

SCHEMBL4673102

COc1ccc(Cc2cc(C(=O)C=C(O)c3nc[nH]n3)cs2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.39
SLC5A2 P31639 1/20 0.36
KDM5A P29375 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
ALDH1A1 P00352 2/20 0.35
ABL1 P00519 1/20 0.35
POLB P06746 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 2/20 0.35
NPC1 O15118 2/20 0.35
MAPT P10636 1/20 0.35
GAA P10253 1/20 0.34
ALOX12 P18054 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
RAB9A P51151 1/20 0.34
FFAR1 O14842 1/20 0.34
PTPN5 P54829 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677932 0.90 PARP1 (0.33) PARP1KDM5AKDM5BALDH1A1ABL1
SCHEMBL4671043 0.89 TSHR (0.39) PARP1ALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL4673824 0.89 DAO (0.40) PARP1ALDH1A1ABL1SMN1; SMN2LMNA
SCHEMBL4678515 0.88 LMNA (0.34) PARP1KDM5AKDM5BALDH1A1ABL1
SCHEMBL4674093 0.88 PARP1 (0.31) PARP1
SCHEMBL4670904 0.87 PARP1 (0.35) PARP1
SCHEMBL4673387 0.85 MAPK8 (0.43) PARP1SLC5A2CYP2C9CYP2C19FFAR1
SCHEMBL4674074 0.83 MAPT (0.36) KDM5AKDM5BALDH1A1ABL1POLB
SCHEMBL4674403 0.82 ALDH1A1 (0.37) KDM5AKDM5BALDH1A1POLBSMN1; SMN2
SCHEMBL4674590 0.82 MAPT (0.53) ALDH1A1POLBSMN1; SMN2LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PARP1 501/4885SLC5A2 1276/4885KDM5A 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.